Renin-Angiotensin and Sympathetic Nervous System Interactions in the Control of Blood Pressure in Fructose-Induced Metabolic Syndrome

Mohammed H Abdulla; Edward J Johns

ISSN: 2161-0479

Journal of Autacoids and Hormones

Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.

Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business

Renin-Angiotensin and Sympathetic Nervous System Interactions in the Control of Blood Pressure in Fructose-Induced Metabolic Syndrome

*Mohammed H Abdulla^1 and Edward J Johns^1,2**
¹Department of Physiology, Western Gateway Building, University College Cork, College Road, Cork, Ireland
²Allianze University College of Medical Sciences, Wazira Medical Square, 13200 Penang, Malaysia
Corresponding Author :	Mohammed H. Abdulla Department of Physiology Western Gateway Building University College Cork College Road, Cork, Ireland E-mail: m.abdulla@ucc.ie
Received April 20, 2012; Accepted April 23, 2012; Published April 24, 2012
Citation: Abdulla MH, Johns EJ (2012) Renin -Angiotensin and Sympathetic Nervous System Interactions in the Control of Blood Pressure in Fructose-Induced Metabolic Syndrome. J Autacoids 1:e105. doi: 10.4172/2161-0479.1000e105
Copyright: © 2012 Abdulla MH, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Related article at Pubmed Scholar Google

Visit for more related articles at Journal of Autacoids and Hormones

View PDF Download PDF

Editorial
Activation of the sympathetic nervous system (SNS) stimulates renin release from the juxtraglomerular cells of the kidneys that leads to the generation of angiotensin I, which is then converted to angiotensin II (Ang II), the major effector peptide of the renin-angiotensin system (RAS). The formed Ang II can facilitate noradrenaline release from the renal sympathetic nerve endings in addition to its effect in the anterior hypothalamus and rostral ventrolateral medulla (RVLM) [1,2]. At RVLM neurons, Ang II acts either postsynaptically, by decreasing K+ currents, or presynaptically by activating vasomotor sympathetic glutamatergic neurons resulting in an increase in sympathetic nerve activity and arterial blood pressure [3-5]. In the renal vasculature, Ang II enhances renal adrenergic function via a presynaptic site of action in anesthetized dogs [6], while in anaesthetised rats Ang II facilitates noradrenergic control at epithelial neuroeffector junctions [7,8]. In conscious rats, Veelken et al. have shown that endogenous Ang II modulates the sympathetic nervous impact on the kidney [9]. On the other hand, it is also recognised that chronic activation of α1- adrenoceptors can result in the down regulation of AT1 receptors [10]. Ang II has been shown to induce transcription and expression of α1- adrenoceptors, mainly α1D-subtype, in rat cultured vascular smooth muscle cells, therefore, some actions of Ang II might be mediated via genomic mechanisms [11]. This mechanism is further illustrated by the finding that the stimulatory effect of Ang II on smooth muscle cell DNA synthesis can be blunted by treatment with the α1-adrenoceptor antagonist prazosin [12]. Therefore, Villalobos-Molina and Ibarra [13] have hypothesized that a long term action of Ang II, through the stimulation of expression and function of vascular α_1D-adrenoceptors, may participate in the development of hypertension.
Thus, it becomes apparent that these two major regulatory systems can interact with each other and contribute to the genesis of many disorders. This interaction has been reported in hypertensive models characterized by insulin resistance an example of which is the spontaneously hypertensive rat [14] which has been described as a model of human insulin resistance syndrome due to reduced insulinmediated glucose disposal and defective fatty acid metabolism [15,16]. A further example is the rat model of fructose-induced hypertension where the SNS and RAS both appear to play a major role [17,18], and can contribute importantly to the sustained hypertension in this model. This view is supported by the observation of increased renal sodium and fluid retention and elevated blood pressure due to hyperactivity of SNS and RAS [19-21]. Accordingly, a consensus has developed that blockade of RAS using ACE inhibitors or AT1 receptor blockers (ARB) may have beneficial effects on insulin resistance in the rat [18,22,23] and in man [24,25]. The usefulness of ACE inhibitors or ARBs involves not only improving glucose metabolism and insulin sensitivity [26] but also restores vascular function. Moreover, it has been reported that the ACE inhibitor captopril blunted the vasoconstrictor responses to the α1-adrenoceptor agonist phenylephrine [27] while the ARB losartan enhanced the vascular responsiveness in 8-week fructose-fed rats [28].
Collectively, all these reports support the notion that Ang II importantly interacts with adrenergic neurotransmission in controlling vascular tone in normal and pathophysiological states. This interaction has been clearly shown in a large number of studies [14,29,30]. Recently, reports have highlighted this interaction between AT1 receptors and α1-adrenoceptors in playing an important role in modulating vascular tone in the fructose-fed rat model [31,32]. However, neither the exact mechanism of this interaction nor its importance has been clearly identified.